Parnaparin and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Parnaparin
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines are blood thinners. Apixaban (Eliquis) blocks a clotting factor called factor Xa, and parnaparin is a heparin-type blood thinner. When you take them together, their effects add up, so your blood becomes even less able to form clots. That means a higher chance of bleeding, and in some cases that bleeding can be serious.
Watch for signs like unusual bruising, pink or red urine, black or bloody stools, bleeding that won't stop, or coughing up blood. Please don't stop either medicine on your own. Your care team can manage this safely by watching you closely and adjusting things as needed. If you notice heavy or unexpected bleeding, get medical help right away.
Additive anticoagulation. Apixaban (direct factor Xa inhibitor) plus parnaparin (a low molecular weight heparin with anti-Xa activity) produces overlapping pharmacodynamic effects and increased bleeding risk. Neither agent is a prodrug; the interaction is straightforwardly additive.
- Magnitude: apixaban plus enoxaparin showed a 50 to 60 percent rise in anti-Xa activity; a similar effect is expected with parnaparin.
- Evidence: probable; severity major.
- Management: avoid unnecessary overlap; if active pathological bleeding occurs, discontinue apixaban (PD effect persists at least 24 h). A specific reversal agent is available; PCC, aPCC, or rFVIIa may be considered. During PCC use, PT/INR/aPTT and anti-Xa monitoring are not useful. Counsel on bleeding signs.
What happens
An increased risk of bleeding and can cause serious, potentially fatal bleeding
Interaction Deep Dive
Giving apixaban, a factor Xa inhibitor, together with another anticoagulant raises bleeding risk. Pharmacodynamic interaction studies involving apixaban showed a 50% to 60% rise in anti-factor Xa activity when apixaban was given alongside enoxaparin. If active pathological bleeding develops, apixaban should be stopped. There is an agent available that reverses apixaban's anti-factor Xa activity. Apixaban's pharmacodynamic effect can be anticipated to last for a minimum of 24 hours following the final dose. Patients should be counseled about the signs and symptoms of blood loss and instructed to report them without delay or present to an emergency room. Prothrombin complex concentrate (PCC), activated prothrombin complex concentrate, or recombinant factor VIIa may be considered. In cases where PCCs are administered, tracking apixaban's anticoagulant effect with a clotting test (PT, INR, or aPTT) or anti-factor Xa (FXa) activity offers no benefit and is not recommended. Absorption of apixaban is decreased by activated oral charcoal, which in turn reduces apixaban exposure1.
Why it happens (mechanism)
Additive anticoagulation
How to manage this interaction
Keep taking both exactly as prescribed unless your prescriber tells you otherwise. Combining two blood thinners is sometimes done deliberately, but your care team will manage the added bleeding risk.
- Your team may monitor you more closely and individualize your dosing.
- Learn the warning signs of bleeding: unusual bruising, red or dark urine, black or bloody stools, nosebleeds that won't stop, coughing or vomiting blood, severe headache, or dizziness.
- Report any of these right away or go to an emergency room.
If bleeding happens, doctors can stop the apixaban and use a reversal agent or clotting-factor products. Its effect can last at least 24 hours after the last dose.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In investigations of pharmacodynamic drug interactions involving apixaban, an increase of 50% to 60% in anti-factor Xa activity was noted when apixaban and enoxaparin were given together 1.
Common questions
Can I take Parnaparin and Apixaban together?
Apixaban and parnaparin are both blood thinners, so taking them together raises your bleeding risk. Keep taking them as prescribed, watch closely for any bleeding, and get emergency help if it occurs. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Parnaparin and Apixaban interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Parnaparin and Apixaban interaction managed?
Keep taking both exactly as prescribed unless your prescriber tells you otherwise. Combining two blood thinners is sometimes done deliberately, but your care team will manage the added bleeding risk. Your team may monitor you more closely and individualize your dosing. Learn the warning signs of bleeding: unusual bruising, red or dark urine, black or bloody stools, nosebleeds that won't stop, coug… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Parnaparin or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ELIQUIS(R) oral film coated tablets, apixaban oral film coated tablets. Bristol-Myers Squibb Company (per Dailymed), Princeton, NJ, 2024. DailyMed
Keep reading about Apixaban
Keep reading about Parnaparin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist